Jason K H Lee1,2, Gary K L Lam1,2, Thomas Shin2,3, Jiyeon Kim1,2, Anish Krishnan1,2, David P Greenberg4,5, Ayman Chit1,4. 1. a Leslie Dan School of Pharmacy , University of Toronto , Toronto , Canada. 2. b Sanofi Pasteur , Toronto , Canada. 3. c Department of Mathematics and Statistics , York University , Toronto , Canada. 4. d Sanofi Pasteur , Swiftwater , PA , USA. 5. e Department of Pediatrics , University of Pittsburgh School of Medicine , Pittsburgh , PA , USA.
Abstract
BACKGROUND: Influenza is responsible for a significant disease burden annually, especially in older adults. This study reviews the relative vaccine efficacy or effectiveness (rVE) of high-dose inactivated trivalent influenza vaccine (HD-IIV3) compared to standard-dose influenza vaccines (SD-IIV3) in adults ≥65 against influenza-associated outcomes to inform evidence-based decision-making to shift clinical practice and standard of care in this population. METHODS: A systematic review was conducted for studies assessing the rVE of HD-IIV3 against probable/laboratory-confirmed influenza-like illness (ILI), hospital admissions, and death in adults ≥65. Results from individual seasons were meta-analyzed and a random-effects model was used to estimate pooled rVEs. RESULTS: After screening 992 studies, seven studies were meta-analyzed. HD-IIV3 demonstrated better protection against ILI compared to SD-IIV3 (rVE = 19.5%; 95% CI: 8.6-29.0%). HD-IIV3 was also more effective at preventing hospital admissions from all-causes (rVE = 9.1%; 95% CI: 2.4-15.3%), as well as from influenza (rVE = 17.8%; 95% CI: 8.1-26.5%), pneumonia (rVE = 24.3%, 95% CI: 13.9-33.4%), and cardiorespiratory events (rVE = 18.2%; 95% CI: 6.8-28.1%). rVE against post-influenza mortality was 22.2% (95% CI: -18.2-48.8%) and 2.5% (95% CI: -5.2-9.5%) against all-cause mortality. CONCLUSIONS: Available evidence suggests HD-IIV3 is more effective than SD-IIV3 at reducing the clinical outcomes associated with influenza infection in older adults and should be considered for routine use in the 65+ population.
BACKGROUND: Influenza is responsible for a significant disease burden annually, especially in older adults. This study reviews the relative vaccine efficacy or effectiveness (rVE) of high-dose inactivated trivalent influenza vaccine (HD-IIV3) compared to standard-dose influenza vaccines (SD-IIV3) in adults ≥65 against influenza-associated outcomes to inform evidence-based decision-making to shift clinical practice and standard of care in this population. METHODS: A systematic review was conducted for studies assessing the rVE of HD-IIV3 against probable/laboratory-confirmed influenza-like illness (ILI), hospital admissions, and death in adults ≥65. Results from individual seasons were meta-analyzed and a random-effects model was used to estimate pooled rVEs. RESULTS: After screening 992 studies, seven studies were meta-analyzed. HD-IIV3 demonstrated better protection against ILI compared to SD-IIV3 (rVE = 19.5%; 95% CI: 8.6-29.0%). HD-IIV3 was also more effective at preventing hospital admissions from all-causes (rVE = 9.1%; 95% CI: 2.4-15.3%), as well as from influenza (rVE = 17.8%; 95% CI: 8.1-26.5%), pneumonia (rVE = 24.3%, 95% CI: 13.9-33.4%), and cardiorespiratory events (rVE = 18.2%; 95% CI: 6.8-28.1%). rVE against post-influenza mortality was 22.2% (95% CI: -18.2-48.8%) and 2.5% (95% CI: -5.2-9.5%) against all-cause mortality. CONCLUSIONS: Available evidence suggests HD-IIV3 is more effective than SD-IIV3 at reducing the clinical outcomes associated with influenza infection in older adults and should be considered for routine use in the 65+ population.
Authors: Sian Williamson; Laura Dennison; Kate Greenwell; James Denison-Day; Fiona Mowbray; Samantha Richards-Hall; Deb Smith; Katherine Bradbury; Ben Ainsworth; Paul Little; Adam W A Geraghty; Lucy Yardley Journal: BMJ Open Date: 2022-06-30 Impact factor: 3.006
Authors: Dana C Miskulin; Daniel E Weiner; Hocine Tighiouart; Eduardo K Lacson; Klemens B Meyer; Taimur Dad; Harold J Manley Journal: Clin J Am Soc Nephrol Date: 2018-10-23 Impact factor: 8.237
Authors: Jessica R Cataldi; Laura P Hurley; Megan C Lindley; Sean T O'Leary; Carol Gorman; Michaela Brtnikova; Brenda L Beaty; Lori A Crane; David K Shay; Allison Kempe Journal: J Gen Intern Med Date: 2021-01-22 Impact factor: 6.473
Authors: Laura Dennison; Sian Williamson; Kate Greenwell; Molly Handcock; Katherine Bradbury; Jane Vennik; Lucy Yardley; Paul Little; Adam W A Geraghty Journal: BMJ Open Date: 2022-04-20 Impact factor: 3.006
Authors: Joshua D Doyle; Lauren Beacham; Emily T Martin; H Keipp Talbot; Arnold Monto; Manjusha Gaglani; Donald B Middleton; Fernanda P Silveira; Richard K Zimmerman; Elif Alyanak; Emily R Smith; Brendan L Flannery; Melissa Rolfes; Jill M Ferdinands Journal: Clin Infect Dis Date: 2021-03-15 Impact factor: 9.079